SingHealth

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

Retrieved on: 
Monday, March 4, 2024
IIT, Regenerative medicine, Research, Microsoft Exchange Server, News, Ageing, Cancer, GMP, Cartilage, Cell, National University Hospital, SingHealth, SKH, B cell, Safety, UC, Transplant, Knee, Patient, Clinical trial, Osteoarthritis, MSC, Umbilical cord, RCA, Pharmaceutical industry

Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.

Key Points: 
  • Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.
  • UC-MSCs are a type of adult stem cells that can be isolated from the umbilical cord tissue after childbirth.
  • UC-MSCs are considered multipotent and are able to differentiate into different cell types, including bone, cartilage, fat, and muscle cells.
  • "Our collaboration with CytoMed marks a significant step in advancing research on allogeneic in-vivo UC-MSC for cartilage repair, including osteoarthritis of the knee.

A Type of Allergy Medicine Might Help Treat Lung Cancer, Research Suggests

Retrieved on: 
Wednesday, December 6, 2023
DOI, Nature, Marc, Allergy, Cancer research, Patient, Lung cancer, National Institutes of Health, TARGET, Cancer, Doctor of Philosophy, Bangladesh Technical Education Board, Cancer Research Institute, Bristol Myers Squibb, Dermatitis, Immunology, Biomarker, Columbia University, Bone marrow, Immunity, Artificial intelligence, MTR, Austrian Academy of Sciences, CRI, Asthma, AACR, FAAD, Hope, Clinical trial, Mouse, Agency, Immunotherapy, Treatment of lung cancer, Human, SingHealth, Neoplasm, NSCLC, Vaccine, Pharmaceutical industry, Science, Chin, Research, MD

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

Key Points: 
  • Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • "Strikingly, we found that IL-4 blockade enhanced lung cancer response to checkpoint blockade in mice and in six lung cancer patients with treatment-resistant disease.
  • "In our relentless pursuit of progress, the Cancer Research Institute (CRI) proudly supports the visionary team at the Icahn School of Medicine at Mount Sinai.

Lunit to Advance Singapore's Healthcare System with AI-powered Solution for Medical Imaging

Retrieved on: 
Thursday, November 30, 2023
Ministry, Health, CGH, Hospital, Bed, MOH, Patient, Medical imaging, Algorithm, SGH, National health insurance, Therapy, Singapore General Hospital, INSIGHT, Diagnosis, NTT DATA, SingHealth, Health care, Changi General Hospital, AI, NTT, Ministry of Health, Medical device, Nursing, Innovation

As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with Lunit INSIGHT CXR.

Key Points: 
  • As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with Lunit INSIGHT CXR.
  • AimSG allows public healthcare institutions to integrate AI imaging solutions, like Lunit INSIGHT CXR, seamlessly into their existing clinical radiology workflow, enhancing medical professionals' diagnostic capabilities and efficiency.
  • Healthcare institutions that have adopted Lunit's AI solution through AimSG have had a positive response and are looking forward to improving the medical imaging workflow.
  • "The AimSG platform enables clinicians from public healthcare institutions to deploy AI algorithms to help them deliver better healthcare to the population.

Wonder Tech's Breakthrough in Language Agnostic Voice AI to Bring Scalable Depression Screening to One Billion People Globally

Retrieved on: 
Tuesday, November 28, 2023
Ministry, DSM-IV codes, Mental, Schizophrenia, Depression, B2B, GDP, Risk, Cardiovascular disease, Insurance, Patient, National University Hospital, Tech, NUH, Anxiety, Bipolar disorder, Diagnosis, Cancer, Speech, SingHealth, Software as a service, PTE, Mental health, Biomarker, AI, DSM-V, Approximation error, Human, Ministry of Health, Medical device, Nursing, Health

LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening.

Key Points: 
  • LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening.
  • The AI model, which identifies depression through detecting nuanced vocal changes, has reached an industry-leading 83% in detection accuracy, surpassing the 80% threshold required for clinical depression detection.
  • With this milestone, Wonder Tech has proven its potential to enable a scalable and adaptable diagnostic tool to help the one billion people affected by mental health disorders worldwide.
  • Wonder Tech also received financial and clinical support from Singapore's Ministry of Health to scale out the solution with leading mental health institutes.

Jana Care, Inc. Announces Initial Closing of a $6 Million Financing Round to Complete Commercialization of its Self-administered Blood Tests for Kidney and Heart Disease

Retrieved on: 
Wednesday, November 8, 2023
SingHealth, Conditional sentence, Patient, Harvard Medical School, CKM, Health, American Heart Association, Massachusetts General Hospital, Chronic kidney disease, Quality of life, IAG, Disease, Risk, Creatinine, Potassium, Hospital, Heart failure, ARCH Venture Partners, Pharmaceutical industry, Medicine

The Company's self-administered, quantitative blood testing platform enables remote risk stratification of chronic kidney disease and heart failure patients.

Key Points: 
  • The Company's self-administered, quantitative blood testing platform enables remote risk stratification of chronic kidney disease and heart failure patients.
  • In addition to its ongoing partnerships with global leaders in diagnostic technologies and pharmaceutical development, Jana Care welcomes lead investor IAG Capital Partners.
  • Jana Care will use the funds to expand the development of Jana Care's quantitative blood testing platform.
  • The platform is designed to enable self-administered blood tests at-home and allows clinicians to review the test results remotely as needed.

Hitachi's Proton Therapy System Now in Use at National Cancer Centre Singapore

Retrieved on: 
Wednesday, October 4, 2023
Proton, Education, Proton therapy, Neoplasm, Respiration, Cancer, Light, Quality of life, Rehabilitation, Research, Carbon, Noetics, Motion, Hospital, SingHealth, Patient, NCCS, Medical imaging

TOKYO, Oct 4, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy system, with which NCCS has completed the first patient treatment as of 11 August 2023.

Key Points: 
  • TOKYO, Oct 4, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy system, with which NCCS has completed the first patient treatment as of 11 August 2023.
  • This marks Hitachi's first proton therapy system to start treatment in Southeast Asia.
  • NCCS is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer.
  • Hitachi provides products and services of particle therapy systems with higher performance and added value, which can be found in leading hospitals around the world, ranging from proton therapy system, heavy ion therapy system to hybrid system combined with the capabilities of proton and carbon therapy.

Healthcare Information Systems Industry Expected to Grow at CAGR of 13.3% from 2023 to 2030 - Grand View Research, Inc.

Retrieved on: 
Wednesday, July 12, 2023
Informatics, IHI, Telehealth, SingHealth, Hospital, CMS, Information, Office of Inspector General, U.S. Department of Health and Human Services, HHS, DME, Health, Big data, Pharmacy, Workflow, Patient satisfaction, RFID, Sunrise, COVID-19, RCM, Kaiser Family Foundation, Intelligence, Medicine, Automation, USD, Pan American Health Organization, Integrated Health Information Systems, HIS, Government, Singapore General Hospital, Investment, EHR, Patient safety, Laboratory, SAN, AI, R, Kids Count Data Book, Pharmaceutical industry

SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.
  • Pan American Health Organization notes that around 30,000 paper-based files will be converted to electronic medical records—largely attributed to health information systems (HIS).
  • An uptick in implementing digital health, electronic health record (EHR) and durable medical equipment (DME) have accentuated the demand for hospital information systems.
  • The global hospital information system market size garnered USD 118.2 billion in 2022 and could witness a robust CAGR of 17.7% through 2030.

Healthcare Information Systems Industry Expected to Grow at CAGR of 13.3% from 2023 to 2030 - Grand View Research, Inc.

Retrieved on: 
Wednesday, July 12, 2023
Informatics, IHI, Telehealth, SingHealth, Hospital, CMS, Information, Office of Inspector General, U.S. Department of Health and Human Services, HHS, DME, Health, Big data, Pharmacy, Workflow, Patient satisfaction, RFID, Sunrise, COVID-19, RCM, Kaiser Family Foundation, Intelligence, Medicine, Automation, USD, Pan American Health Organization, Integrated Health Information Systems, HIS, Government, Singapore General Hospital, Investment, EHR, Patient safety, Laboratory, SAN, AI, R, Kids Count Data Book, Pharmaceutical industry

SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.
  • Pan American Health Organization notes that around 30,000 paper-based files will be converted to electronic medical records—largely attributed to health information systems (HIS).
  • An uptick in implementing digital health, electronic health record (EHR) and durable medical equipment (DME) have accentuated the demand for hospital information systems.
  • The global hospital information system market size garnered USD 118.2 billion in 2022 and could witness a robust CAGR of 17.7% through 2030.

Zeta Surgical Announces Successful Treatment of First Patient in Neurosurgical Navigation Clinical Trial at Singapore's National Neuroscience Institute

Retrieved on: 
Thursday, June 22, 2023
NNI, Tan Tock Seng Hospital, Deafness in the Democratic Republic of the Congo, Clinical trial, Medicine, SingHealth, Harvard Medical School, Neuroscience, Singapore General Hospital, Hospital, Neurosurgery, Patient, Entrepreneurship, Safety, Medical device, Newsweek

SINGAPORE, June 22, 2023 /PRNewswire/ -- Zeta Surgical, a surgical robotics and mixed reality company, has successfully treated its first patient using the Zeta Cranial Navigation System as part of their first-in-human trial at Singapore's National Neuroscience Institute (NNI).

Key Points: 
  • SINGAPORE, June 22, 2023 /PRNewswire/ -- Zeta Surgical, a surgical robotics and mixed reality company, has successfully treated its first patient using the Zeta Cranial Navigation System as part of their first-in-human trial at Singapore's National Neuroscience Institute (NNI).
  • The trial is led by NNI Associate Consultant Dr. Min Wei Chen and conducted at Singapore General Hospital and Tan Tock Seng Hospital.
  • "This trial marks our first step towards making surgical guidance truly accessible across neurosurgery and neuroscience," says Raahil Sha, Co-Founder and Chief Technology Officer of Zeta Surgical.
  • "We are thrilled to be partnering with NNI in our mission to make surgeries more precise, safe, and effective."

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Retrieved on: 
Tuesday, May 9, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Tissue, Graft-versus-host disease, Heart, SingHealth, Partnership, Boehringer, Doctor of Philosophy, Neoplasm, Infection, Survival, Pharmacokinetics, Quality of life, Scar, PDE4B, Inflammation, DSM-IV codes, Lung, Pulmonary fibrosis, Boehringer Ingelheim, Duke–NUS Medical School, Fibrosis, Death, Discovery, Patient, Vicki Belo, Circulatory system, Biology, Liver, IPF, Safety, Pharmaceutical industry

Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.

Key Points: 
  • Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.
  • The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte.
  • ‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues.
  • Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis.